Channel Wealth
VKTX icon

Channel Wealth’s Viking Therapeutics VKTX Stock Holding History

Channel Wealth’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.45M Sell
44,571
-5,457
-11% -$189K 0.31% 63
2026
Q2 		$1.95M Sell
50,028
-47,929
-49% -$1.55M 0.44% 58
2026
Q1 		$3.19M Buy
97,957
+22,482
+30% +$723K 0.77% 47
2025
Q4 		$2.66M Buy
+75,475
New +$2.67M 0.67% 50

Other funds holding VKTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Channel Wealth's VKTX Position: Q3 2026 in Review

Channel Wealth reduced its Viking Therapeutics (VKTX) stake by 11% in Q3 2026, selling an estimated $189K and leaving 44,571 shares worth $1.45M. The position accounts for 0.31% of the portfolio, ranked #63.

Channel Wealth first reported a position in VKTX in Q4 2025 and has held it in 4 quarters since. The position peaked at $3.19M in Q1 2026. 182 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Channel Wealth held 44,571 shares of Viking Therapeutics worth $1.45M as of Q3 2026.
  • Channel Wealth sold 5,457 Viking Therapeutics shares in Q3 2026, an estimated $189K.
  • Viking Therapeutics made up 0.31% of Channel Wealth's portfolio in Q3 2026, its #63 holding.
  • Channel Wealth first reported a position in Viking Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Channel Wealth's Viking Therapeutics position peaked at $3.19M in Q1 2026.
  • 182 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Channel Wealth's 13F filing for Q3 2026, filed 6 Nov 2026.